Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K
Cross-reactivity00:42

Cross-reactivity

28.7K
Overview
28.7K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.7K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.7K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tocilizumab-induced psoriatic eruption : a case report and a case-based review.

Rheumatology international·2024
Same author

IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans.

Clinical and experimental immunology·2021
Same author

Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2019
Same author

Natural Immunomodulators.

Journal of immunology research·2018
Same author

F376A/M388A-solulin, a new promising antifibrinolytic for severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Innovating immune tolerance induction for haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Related Experiment Video

Updated: May 4, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K

Predictive immunogenicity of Refacto AF.

S Delignat1, Y Repessé, L Gilardin

  • 1Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche en Santé (UMR S), Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, UMR, Centre de Recherche des Cordeliers, Paris, France; Université Paris Descartes, UMR S, Centre de Recherche des Cordeliers, Paris, France.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|December 31, 2013
PubMed
Summary
This summary is machine-generated.

This study compared the immunogenicity of Refacto AF, a recombinant factor VIII (FVIII), against full-length products. Refacto AF showed similar or lower immunogenicity, suggesting it

Keywords:
factor VIIIhaemophilia Aimmunogenicityinhibitorspredictionrefacto® AF

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.5K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

7.6K

Related Experiment Videos

Last Updated: May 4, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.5K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

7.6K

Area of Science:

  • Immunology
  • Hematology
  • Biotechnology

Background:

  • Therapeutic factor VIII (FVIII) administration for hemophilia A can lead to inhibitory anti-FVIII antibodies in up to 30% of patients.
  • The origin and structure of FVIII products (plasma-derived vs. recombinant, full-length vs. B-domain deleted) are debated as risk factors for inhibitor development.

Purpose of the Study:

  • To compare the immunogenicity of Refacto AF, a third-generation recombinant B-domain deleted FVIII, with two recombinant full-length FVIII products (Helixate and Advate).
  • To assess the potential risk of inhibitor development associated with different FVIII formulations.

Main Methods:

  • Compared binding to the CD206 receptor and dose-dependent endocytosis by dendritic cells (DCs) for Refacto AF, Helixate, and Advate.
  • Evaluated FVIII-specific T-cell activation by FVIII-loaded DCs.
  • Assessed the induction of inhibitory anti-FVIII IgG in FVIII-deficient mice.

Main Results:

  • Refacto AF showed lower endocytosis by DCs at elevated concentrations compared to full-length products.
  • At lower concentrations, Refacto AF's endocytosis and T-cell activation were comparable to Helixate and Advate.
  • Inhibitory anti-FVIII IgG levels induced by Refacto AF in mice were lower or equal to those induced by Helixate and Advate.

Conclusions:

  • The immunogenicity of Refacto AF is predicted to be identical to or lower than that of available recombinant full-length FVIII products.
  • These findings contribute to understanding FVIII product characteristics and their impact on inhibitor development in hemophilia A.